HCG brings together significant numbers of doctors in Kolkata to reimagine how cancer
care in India can deliver more precise and predictable outcomes

HealthCare Global Enterprises Ltd. (HCG) hosted a high-impact Continuing Medical
Education (CME) programme in Kolkata titled “Decoding the Future of Cancer Care –
Harnessing Next-Generation Intelligence to Transform Patient Outcomes.” The CME was led
by Dr. B. S. Ajaikumar, Founder and Chairman, HCG, and brought together over 400
doctors, including HCG clinicians and senior external oncologists and multidisciplinary
specialists from across the region.

The CME underscored the imperative of delivering the right treatment, the first time,
through the integration of clinical research, structured data, and precision oncology. The
programme featured a keynote address by Dr. Ajaikumar, followed by a panel discussion
moderated by him, examining how precision medicine, genomics, advanced diagnostics, and
outcomes-driven data systems are redefining care pathways and enabling more meaningful
improvements in patient outcomes.

Speaking at the CME, Dr. B. S. Ajaikumar said:
“As oncology continues to evolve in complexity, the responsibility of leadership is to ensure
that innovation is applied with clinical rigour and evaluated through outcomes. Delivering
the right treatment, the first time, requires disciplined data collection, longitudinal outcome
tracking, and evidence-based, multidisciplinary decision-making.

Platforms such as this CME enable informed clinical dialogue and collective learning, while
reinforcing a research-led, data-driven approach—reflected in our peer-reviewed
publications and international scientific presentations—that strengthens consistent,
outcomes-led cancer care for the benefit of patients.”

During his address, Dr. Ajaikumar also emphasised the importance of preventing cancer
recurrence by developing a deeper understanding of cancer biology, disease behaviour, and
treatment response over time. He highlighted how structured clinical research, systematic
data collation, and long-term outcome tracking play a critical role in refining treatment
strategies and translating scientific insights into more durable patient outcomes.

Discussions during the CME focused on reducing diagnostic delays, optimising therapeutic
choices, and ensuring timely, evidence-based interventions. Key areas included recent
advances in targeted therapies and immunotherapy, the integration of genomics into
routine clinical decision-making, evolving disease patterns alongside emerging technologies

such as advanced diagnostics and AI-enabled tools, and strengthening the use of outcomes
measurement and registries to continuously improve the quality of cancer care.
Adding to the discussion, Dr. Manish Mattoo, CEO & Executive Director, HealthCare Global
Enterprises Ltd., said:

“The future of oncology lies in building systems that consistently support the right
treatment decisions at the right time. At HCG, we are focused on integrating research, data,
and technology into care delivery to improve predictability, efficiency, and outcomes across
the cancer care continuum. Knowledge-sharing forums such as this CME are critical enablers
of that transformation.”

Highlighting the regional relevance, Dr. Rupali Basu, Regional Business Head – East & AP,
HCG, said:

“Eastern and North-Eastern India are witnessing evolving cancer trends and a growing need
for advanced, accessible oncology care. Through focused knowledge exchange, clinical
collaboration, and future-ready infrastructure, including Outreach Centres, we are working
to ensure patients receive high-quality cancer care closer to home.”

The CME featured case-based discussions from HCG’s multidisciplinary care pathways and
deliberations on operational challenges such as access to advanced testing, coordination
across specialties, and the need for clinician training to interpret complex genomic data. The
programme concluded with an interactive Q&A session and networking, fostering
collaboration across specialties including Radiation Oncology, Medical Oncology, Surgical
Oncology, General Surgery, General Medicine, Urology, Nephrology, ENT, and Maxillofacial
Surgery—reinforcing the importance of a multidisciplinary, outcomes-driven approach to
modern cancer care.